STAAR Surgical (STAA) is back in focus as Wall Street watches for a first quarter earnings update. The report is expected to show sequential improvement and a move from loss to profit, which is sharpening attention on profitability trends.

Recent trading has been choppy, with the share price down about 2% over the past week but still showing a 54.28% 90 day share price return and a 31.67% 1 year total shareholder return. These figures indicate that the stock has recently experienced significant share price appreciation ahead of the earnings update.

If you are watching how medical technology stories like STAAR Surgical develop, it can also be useful to see what is happening across healthcare AI stocks through 34 healthcare AI stocks

With STAAR Surgical shares up strongly over the past 90 days and trading slightly above some analyst targets, the key question now is simple: is there still value left on the table, or has the market already priced in future growth?

Most Popular Narrative: 26.4% Overvalued

STAAR Surgical's most followed narrative pegs fair value at about $21.11 per share, compared with a last close of $26.69. This puts the market price above that narrative view and centers the debate on whether expectations have run too far ahead.

The analysts have a consensus price target of $21.11 for STAAR Surgical based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $27.0, and the most bearish reporting a price target of just $16.0.

Want to see what is baked into that gap between fair value and today’s price? Revenue growth assumptions, margin rebuild and a punchy future earnings multiple all sit at the core of this narrative, and the details behind those inputs are where the real story starts to get interesting.

Result: Fair Value of $21.11 (OVERVALUED)

However, there are still clear pressure points, including China-dependent revenue and reliance on a single distributor, that could quickly challenge the current overvaluation narrative.

Another View: Cash Flows Point To A Tighter Margin Of Safety

Analysts see STAAR Surgical as 26.4% above their $21.11 fair value, but the Simply Wall St DCF model paints a different picture. On that cash flow view, the stock at $26.69 sits about 3.1% below an estimated $27.53 fair value, which is a much narrower gap for investors to weigh.

For anyone comparing these two signals, it raises a simple question: which set of assumptions do you trust more, analyst targets or the cash flows embedded in the SWS DCF model?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out STAAR Surgical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between caution and optimism, it makes sense to move quickly and test the numbers yourself before the next update hits the market. To see what is driving the optimism and how those potential rewards stack up against the risks, review the 2 key rewards.

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that fit your style, so put the Simply Wall St Screener to work for you.

• Hunt for quality at a discount by scanning 49 high quality undervalued stocks that pair solid fundamentals with prices that may still leave room for upside.
• Strengthen your income potential by reviewing 12 dividend fortresses that focus on higher yields with an emphasis on resilience.
• Dial back risk without stepping away from the market by checking 71 resilient stocks with low risk scores that screen for more stable profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.